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ABSTRACT
Background: Screening of alloantibodies in patients is not yet done in district hospitals of 
Rwanda. The practice is to transfuse ABO/D compatible blood following an immediate 
spin crossmatch (IS-XM) or indirect antiglobulin test crossmatch (IAT-XM).
Objectives: To assess the risk of red blood cell (RBC) alloimmunisation associated with 
the use of IS-XM compared to the IAT-XM in patients receiving blood transfusions in 
district hospitals in Rwanda. 
Design: A cross-sectional comparative descriptive study.
Setting: Four Rwandan district hospitals. Kirehe and Nyanza hospitals used IS-XM 
while Muhima and Ruhengeri hospitals used IAT-XM. 
Subjects: Blood samples were obtained from 187 patients (101 with IS-XM and 86 with 
IAT-XM) transfused in January, February, October, and November of 2012.  
Results: The median age of blood recipients was 31 years (7 - 80) and 36% of them were 
male. Sixteen specific antibodies were identified in 12 patients: anti-RH1/D (2),anti-
RH2/C (2), anti-RH3/E (2),anti-RH4/c (1),anti-RH5/e (2),anti-LE1/Lea (2),anti-JK1/Jka 
(1),anti-JK2/Jkb (1),anti-KEL1/K (1),anti-MNS1/M (1),and autoantibody (1).The global 
prevalence of red blood cell (RBC) alloimmunisation was 6.4 % (12/187). That prevalence 
was significantly higher in the IS-XM group (10.4%) than in the IAT-XM group (2.3%) 
with an odds ratio of 4.8; [95% CI=1.2-19.8]; and a p-value of 0.031.
Conclusion: The prevalence of red blood cell (RBC) alloimmunisation in 187 patients 
receiving blood transfusions was 6.4% and was higher in recipients from hospitals 
using IS-XM, with Rhesus (RH) system antibodies widely predominant (56.2%).We 
recommend that IAT-XM be used in all district hospitals in Rwanda to minimise this 
risk. 
INTRODUCTION
Red blood cell (RBC) alloimmunisation is the 
formation of single or multiple antibodies to red blood 
cell antigens following transfusion, transplantation 
or pregnancy. Clinically significant antibodies are 
those known to cause haemolytic disease of the 
newborn (HDN), haemolytic transfusion reaction, or 
shortened survival of transfused red blood cells. To 
prevent alloimmunisation, sensitive pretransfusion 
techniques, such as blood group typing combined 
with screening of alloantibodies (“type and screen”) 
or compatibility testing shall be those that detect 
clinically significant antibodies. They shall include 
incubation at 37°C prior to antiglobulin test using 
reagent red blood cells that are not pooled (1).
 Compatibility “tube” testing is carried out in 
three main phases (D. Joe Chaffin, Pretransfusion 
testing": Basic Immunohematology part 2). The 
first phase, called “immediate spin” (IS),consists  in 
combining two drops of the recipient serum and 1 
drop of a 2 to 5% saline suspension of the donor RBCs 
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with centrifugation for 15 to 30 seconds. This phase 
enables detection of ABO incompatibility and cold-
reactive antibodies; the latter are Ig M antibodies that 
are not clinically significant. In the second phase, a 
potentiator medium (low ionic strength saline [LISS], 
polyethylene glycol [PEG], or bovine albumin) is 
added and the solution is incubated at 37ºC. The 
incubation period differs depending on the medium: 
10-15 min for LISS, 15 min for PEG, and 15-30 min for 
bovine albumin. The third phase consists in adding 
antihuman globulin (AHG), an antibody against 
human immunoglobulins and/or complement to the 
mixture; this phase is also called indirect antiglobulin 
test (IAT) (2, 3). The final phase is crucial for detecting 
weak anti-A or anti-B and warm-reacting IgG 
antibodies, which are clinically significant and not 
detected by IS-XM (4). Other methods of compatibility 
testing, such as column agglutination (“gel”) testing 
and solid phase adherence assay (SPAA), are used in 
different countries(2,3). Each hospital must determine 
its preferred testing method and ensure adequate lab 
capacity to perform the selected procedure. IS-XM is 
a safe method only in centres where sera of donor 
and patient are screened for clinically significant 
antibodies and the screening is negative (1, 5, 6).
 In district hospitals of Rwanda, screening of 
alloantibodies in patients is not performed. The 
practice is to transfuse ABO/D compatible blood 
following an IS-XM in most cases or IAT-XM in 
few hospitals. Despite this variability in practice, 
there are no studies to our knowledge that assess 
alloimmunisation outcome of blood transfusion in 
Rwandan patients.
 The aim of this study was to measure the risk of 
RBC alloimmunisation in Rwandan patients receiving 
RBC transfusion where IS-XM testing is used versus 
IAT-XM testing in pretransfusion crossmatch. We 
determined the prevalence and specificities of RBC 
alloantibodies in transfused patients from four 
different district hospitals employing these two 
crossmatch testing techniques.
MATERIALS AND METHODS
Study design: Using cross-sectional design and 
systematic sampling, we selected a total of 187 
transfused patients with different diseases in four 
district hospitals of different provinces of Rwanda. 
Study sites included four hospitals: Muhima, Nyanza, 
Ruhengeri and Kirehe District Hospitals. Kirehe and 
Nyanza Hospitals were using IS-XM and Muhima 
and Ruhengeri were using IAT-XM. A nurse at each 
hospital recruited patients for the study and a doctor 
at each hospital facilitated data collection and notified 
patients of results; both received basic information 
and training regarding the study.
 Patients receiving transfusions were recruited 
in four months, February, March, October and 
November of 2012. Eligibility criteria included 
inpatients that were at least seven years of age and 
had received at least one transfusion. Children below 
seven years were excluded to ensure adequate volume 
of blood samples for immunohaematology analyses. 
Prior to discharge, enrolled patients were given 
information about the study and were provided with 
a follow-up appointment for repeat blood testing. 
Follow-up appointments were scheduled at least four 
weeks after transfusion, allowing sufficient time for 
minimal reactive antibody formation (7). Depending 
on the date of transfusion, the follow-up period was 
between four and12 weeks. Data collection and blood 
samples were taken in the last week of April 2012 for 
those transfused in February and March and in the 
last week of December 2012 for those transfused in 
October and November. 
Data collection: We used a structured questionnaire 
to record demographic and transfusion history 
characteristics, including: age, sex, parity, number 
of transfusion episodes, number of transfused units 
of packed red blood cells, clinical indication for 
the transfusion, type of transfused blood product, 
and technique used in pretransfusion crossmatch 
testing (IS-XM or IAT-XM). Prior to patient 
discharge, information about the study was given 
to patients and the questionnaire was completed by 
a doctor. Patients returned 4 to 12 weeks later for 
blood sample collection and the questionnaire was 
updated with the time period between transfusion 
and blood sample collection. After informed consent 
(assent for patients below 17 years) was obtained, 
six to nine milliliters of blood was collected in 
EDTA (ethylenediaminetetraacetic acid) vacutainer 
test tubes. Within 12 hours, samples underwent 
centrifugation at 3000 rpm lasting three minutes. 
Plasma samples were extracted and kept at -30ºC 
and red blood cell samples at 2 to 6ºC in the Regional 
Blood Centre of Rwamagana in Eastern Province 
(Rwanda) until they were transported to the Blood 
Bank of Liège in Belgium where laboratory analyses 
were performed. 
Laboratory investigations: Immunohaematology 
analyses of blood samples were performed by the 
blood bank of the University Hospital of Liège. 
Plasma samples were screened for the presence 
of red blood cell alloantibodies (detection of 
irregular antibodies) using an automated technique, 
Immucor Capture-R Ready-Screen (4) (Immucor® 
Néo®) (sensitivity 88.3%, specificity 94.3%) (8). 
This technique uses microplate wells coated with 
a standard 4-cell panel of reagent group-O RBCs. 
When the antibody screening was positive, by similar 
technique, antibody identification was performed by 
testing the plasma samples with commercial panels 
of 14 reagent RBCs of selected phenotypes with one 
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positive and one negative control-cell. While some 
alloantibodies could be identified by this automated 
technique, others required further analysis using 
gel centrifugation technique (Diamed-ID®, Alba 
Bioscience®, Edinburgh) with a standard 3-cell 
panel of reagent group-O RBCs for screening and 
11 phenotyped group-O RBCs for identification. 
In this gel technique, enhancers were “LISS/
Coombs” and “NaCl/papaïne” (overall sensitivity 
79%: 57% in Coombs and 59.3% in papaïne with 
overall specificity 98.6%) (Jérôme de MARCHIN 
and Christiane GERARD ,Comparison of Immuno-
Capture (Immucor® Galileo®) assay to the Gel 
(Diamed®) in pre-transfusion testing in a Blood Bank, 
CHU of Liège ). The algorithm combining these two 
techniques allows the identification of more specific 
antibodies (9). 
 Patients were considered to be alloimmunised 
if antibodies to one or more RBC antigens could be 
identified. One patient with panreactive panels in 
both indirect antiglobulin test and papaïne, followed 
by a positive direct Coombs test was also considered 
alloimmunised.
Statistical analysis: Data entry and statistical analysis 
was performed using STATA/IC 12.1 for Windows. 
Descriptive analysis included frequency tables 
and mean or median calculation. Odds ratios for 
associations (with exact or test–based confidence 
interval), Pearson Chi-squared (chi-2) or Fisher’s exact 
test (when assumptions were not met for chi-2) and 
Mantel-Haenszel chi-2 for stratification were used 
to measure the relationship between red blood cell 
(RBC) alloimmunisation and related exposure factors. 
Pretransfusion crossmatch technique (IS-XM or IAT-
XM) was the main factor to analyze. Other factors 
known to be associated with RBC alloimmunisation in 
other studies were also analysed; these include gender, 
number of parity, and number of transfusion episodes. 
Furthermore, we analysed possible confounders in 
the relationship between RBC alloimmunisation and 
pre-transfusion crossmatch technique by adjusting for 
gender, number of parity and number of transfusion 
episodes. Groups were assumed to differ significantly 
when the p-value was lower than 0.05.
Ethical consideration: This research has been approved 
by the Rwanda National Ethical Committee and was 
reviewed by the Rwanda Biomedical Centre/National 
Health Research Committee, where we obtained two 
different ethical and scientific approvals, respectively. 
Amendments to the study protocol during our study 
process were sent to both these institutions.
RESULTS 
Demographic and transfusion related results: Of the 187 
transfused patients who were recruited, 86 (46.0%) 
were from the two hospitals using IAT-XM and 101 
(54.0%) were from the two hospitals using IS-XM. 
Females were predominant (64%) with sex ratio of 
1.75. Age ranged from 7 to 80 years; the median age 
was 31 years. At the time of blood sample collection, 
74.3% of patients reported one lifetime blood 
transfusion, 16.6% reported two while 9.1% were 
polytransfused. Packed RBCs were transfused in 
93.0% of the cases, whole blood in 3.2%, platelets in 
3.2% and plasma in 0.5%. Mean number of units by 
transfusion was 2 ± 0.65 (standard deviation). Major 
indications for transfusion were: hematology related 
diseases (35.3%), obstetric hemorrhage (33.7%), 
infections (16.0%), and other conditions, such as renal 
or cardiac failure (15.0%). Mean time between last 
transfusion and blood sampling was 7 ± 3.6 weeks 
(standard deviation).
Antibodies detection and identification: Laboratory 
investigations showed 19 of 187 patients (10.2%) with 
reactive irregular antibodies. Panels for antibody 
identification specified 16 antibodies in 12 patients 
(6.4%). We were not able to determine specific 
antibodies in the remaining seven patients (3.7%), 
and so these samples were considered as missing 
for antibodies during statistical analysis. Hence, 
RBC alloimmunisation in our studied population is 
6.4%. Among the 12 alloimmunised patients, eight 
patients had single specificity antibodies and 4 had 
mixed specificities. Table 1 shows the specificities 
of identified antibodies, with 9 (56.2%) belonging 
to the Rhesus blood group system, 2 (12.5%) to the 
Lewis system, 2 (12.5%) to the Kidd system, 1(6.3%) 
to the Kell system, 1 (6.3%) to the MNS system, and 1 
(6.3%) showed panreactive panel with positive direct 
Coombs test (auto-antibody). 
April 2013 East african MEdical Journal    127
Table 1
Specificities of 16 RBC alloantibodies identified in 12 (6.4%) transfused patients in Rwanda
Blood group system RBC alloantibody specificity Number of antibodies 
(respectively)
Frequency (%)
Rhesus RH1/D , RH2/C, RH3/E , 
RH4/c , RH5/e
2,2,2,1,2 56.2
Lewis LE1/Lea 2 12.5
Kidd JK1/Jka ,JK2/Jkb 1, 1 12.5
Kell KEL1/K 1 6.3
MNSs MNS1/M 1 6.3
Panreactive* Auto 1 6.3
Total 16 100%
*RBC with positive auto-antiglobulin test
Risk factors of red blood cell (RBC) alloimmunisation: 
Excluding the 7 patients (5 in IS-XM test and 2 
in IAT-XM test) with indeterminate profiles, 10 
patients among 96 (10.4%) in the IS-XM group were 
alloimmunized versus 2 patients (2.3%) among 84 in 
the IAT-XM group, with odds ratio (OR) of 4.8, [95% 
CI = 1.2 -19.8] and a p-value = 0.031. Female patients, 
multiparous women and polytransfused patients 
were respectively 1.2; 1.9 and 2.2 times more likely 
to develop alloantibodies than other patients in their 
corresponding groups but these associations were not 
statistically significant. To check confounding factors, 
the Mantel-Haenszel (M-H) chi-squared (chi2) test of 
the relationship between RBC alloimmunisation and 
pretransfusion crossmatch technique adjusted for 
number of transfusion episodes remained significant 
with a p-value = 0.040. The M-H chi2 after stratification 
by gender and number of parity was not found due 
to small number of cases (antibodies) observed in 
respective strata. Table 2 summarises our findings 
related to risk factor analysis.
Table 2
Risk factors  in 12 (6.4%) alloimmunised patients in Rwanda
Variable in categories Number 
of 
patients* 
N u m b e r 








Crossmatch test    0.031†
     IS-XM 96 10 (10.4) 4.8  1.2 -19.8(tb)
     IAT-XM 84   2 (2.3) 1  
Gender    0.773†
     Females 113   8 (7.0) 1.2 0.3 -5.7(exc) 
     Males 67   4 (5.9) 1  
Parity**    0.708††
     Nulliparous 42   2 (4.8) 1  
     At least one pregnancy 71   6 (8.5) 1.9 0.3- 19.5(exc) 
Number of transfusion episodes    0.187††
     One lifetime transfusion 134   7 (5.2) 1  
     More than one transfusion 46   5 (10.9) 2.2 0.5-8.6 (exc)
*The 7 patients with indeterminate profiles are excluded; **only in females; (tb) test based confidence interval; 
(exc) exact confidence interval; †Pearson Chi2; ††Fisher's exact.
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DISCUSSION
This is the first ever study carried out to compare the 
frequency of red blood cell (RBC) alloimmunisation 
with specific antibodies in different pretransfusion 
crossmatch techniques after blood transfusion in 
Rwanda. The high proportion of women in this 
study was due to the inclusion of Muhima hospital, 
which only provides maternity services. Additionally, 
obstetric hemorrhage in women is common in Africa, 
especially in rural areas; leading to higher rates of 
transfusion in females (10) .The high prevalence of 
packed RBC transfusion (93.0 % of the cases) showed 
a low utilisation of other blood products. While 
RBC transfusion is more common in the context of 
emergency transfusions, as it is the case in district 
hospitals of Rwanda, this may also indicate a lack 
of clinician and blood bank staff awareness about 
the indications of blood product use, blood ordering 
practices and storage, as was shown in two studies 
published in 2010 assessing clinical transfusion 
practice and interface between blood preparation 
and use in Uganda (11, 12).
 The prevalence of RBC alloimmunisation, 
excluding seven indeterminate profiles, was 6.4%. 
This prevalence may be an underestimate compared 
to the total reactive irregular antibody detection 
rate of 10.2%. The 6.4% rate  of alloimmunisation 
in our hospitals is comparable to that seen in two 
studies carried out in patients receiving transfusions 
in Ugandans for  different diseases and for sickle 
cell anemia (6.1% in both studies )(13,14). Rates of 
alloimmunisation in other studies show a wider range: 
a study in polytransfused patients in Mali revealed 
10.3% alloimmunisation whereas a study in Malawi 
showed 1.1% alloimmunisation (but included patients 
who had not received blood transfusion)(15,16) .The 
predominance of alloantibodies (56.2%)  belonging 
to the Rhesus blood system in this study (Table 1) is 
compared to the results of the two studies conducted in 
Uganda ( 53.8% and 76.9% of alloantibodies belonging 
to RH blood system ) (13, 14). That predominance 
is also explained by a high proportion of variant 
antigens (mainly D and C) within the RH blood 
system found in Afro-Caribbean population (17, 
18).In the same context of alloimmunisation due to 
RH system antigens, Norol F et al. showed that RBC 
alloimmunisation can be reduced by 75% if matched 
RBCs for RH and Kell antigens are transfused instead 
of standard matched red blood cells (ABO/D only) 
(19).
 In our study, pretransfusion crossmatch by IS-
XM was significantly associated with a higher risk 
of RBC alloimmunisation (4.8 times more likely to 
cause RBC alloantibodies than IAT-XM). This was also 
demonstrated in a study conducted by T. Oduola et 
al., in which incompatible residual reactions (1.2%) 
were observed by both LISS-AHG (IAT) and full 
AHG crossmatches when ABO/D compatible blood 
issued by IS-XM was examined (4, 5). In our study, 
there was no significant relationship between RBC 
alloimmunisation with sex, parity, and number of 
transfusion episodes, as was seen in other studies 
(13, 20, 21, 22). Furthermore, these variables did 
not confer a confounding effect on the relationship 
between RBC alloimmunisation and XM tests.
In conclusion, the risk of developing RBCs 
alloantibodies is higher in patients where IS-XM 
pretransfusion crossmatch is used, compared to 
IAT-XM testing with predominance of RH system 
antibodies. We recommend using a standard 
operating procedure with IAT-XM in blood banks 
of district hospitals of Rwanda to minimize the risk 
of alloimmunisation. While the roll out of IAT-XM 
can be easily implemented, surveillance procedures 
must be put in place to assure the sustainability and 
quality of the technique in the whole country.
STUDY LIMITATIONS
Our sample size was limited by financial constraints. 
However, potential sources of bias were controlled by 
a good communication with participants to limit non 
respondents, by using controlled procedures for blood 
sample storage, transport and laboratory analyses.
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